What we do
Autologous Cell Therapy
Allogenic Cell Therapy
Enzyme Therapy
Medical Device
The healiva® Approach
Our pipeline products address the entire spectrum of the wound-care process for chronic wounds, from key first steps to the completion of closure.
Autologous Epidermal Equivalent
Chronic Wounds
Our personalised solution that promotes the complete closure of chronic wounds, including vascular leg ulcers.
Allogenic Cell Spray
Chronic Wounds
Our scalable treatment for chronic leg ulcers that are not responding to standard of care, using automated manufacturing.
Enzymatic Debrider Spray
Chronic & Acute Wounds
Our easy-to-use, and painless enzymatic debridement spray clears dead tissue to support physiological healing processes.
Autologous Cell Grafting
Medical device
Our first-in-class autologous cell grafting medical device is rapid, cost-effective, intuitive, and safe to use, enabling personalised treatment of wounds at the point-of-care.
Chronic Wounds
#1 Wound bed preparation
healiva® 003: Enzymatic Debrider spray cleans wounds, creates barrier to infection, and kickstart physiological repair mechanisms.
#2 Intervention: Autologous Epidermal Equivalent and Allogenic Cell Spray.
healiva® 002/004 Cell therapy interventions for early stage chronic wounds (Chronic Venous Leg Ulcers (VLU) & Diabetic Foot Ulcers /DFU).
healiva® 001 Cell therapy interventions for severe, hard to heal wounds (Recalcitrant Venous Leg Ulcers).
#3 Completion of wound closure.
Headquarters
healiva® SA
Address: Corso Elvezia 4, Lugano, Switzerland
Get in touch
healiva® is a Bioseutica backed innovative Swiss startup venture located in Lugano combining digital health, enzyme technology and cell therapy to deliver personalised and precision solutions for regenerative biology.
Headquarters
